BRPI0906094A2 - composto e método de tratamento de diabetes do tipo ii - Google Patents
composto e método de tratamento de diabetes do tipo iiInfo
- Publication number
- BRPI0906094A2 BRPI0906094A2 BRPI0906094A BRPI0906094A BRPI0906094A2 BR PI0906094 A2 BRPI0906094 A2 BR PI0906094A2 BR PI0906094 A BRPI0906094 A BR PI0906094A BR PI0906094 A BRPI0906094 A BR PI0906094A BR PI0906094 A2 BRPI0906094 A2 BR PI0906094A2
- Authority
- BR
- Brazil
- Prior art keywords
- type
- treatment method
- diabetes compound
- diabetes
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3387708P | 2008-03-05 | 2008-03-05 | |
| PCT/US2009/035111 WO2009111239A2 (en) | 2008-03-05 | 2009-02-25 | Pyrrolidine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0906094A2 true BRPI0906094A2 (pt) | 2016-07-05 |
| BRPI0906094B1 BRPI0906094B1 (pt) | 2019-11-12 |
| BRPI0906094B8 BRPI0906094B8 (pt) | 2021-05-25 |
Family
ID=41054296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0906094A BRPI0906094B8 (pt) | 2008-03-05 | 2009-02-25 | composto |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8022096B2 (pt) |
| EP (1) | EP2252582B1 (pt) |
| JP (1) | JP5586484B2 (pt) |
| KR (1) | KR101634656B1 (pt) |
| CN (1) | CN101970402B (pt) |
| AU (1) | AU2009222198B2 (pt) |
| BR (1) | BRPI0906094B8 (pt) |
| CA (1) | CA2717518C (pt) |
| ES (1) | ES2515194T3 (pt) |
| MY (1) | MY155630A (pt) |
| NZ (1) | NZ587911A (pt) |
| RU (1) | RU2494094C2 (pt) |
| TW (1) | TWI385163B (pt) |
| WO (1) | WO2009111239A2 (pt) |
| ZA (1) | ZA201006329B (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN105142621A (zh) | 2012-10-24 | 2015-12-09 | 国家健康科学研究所 | 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂 |
| EP3116469B1 (en) | 2014-03-10 | 2018-10-03 | Mary Kay, Inc. | Skin lightening compositions |
| CN104447478B (zh) * | 2015-01-13 | 2016-04-13 | 佛山市赛维斯医药科技有限公司 | 一种含腈基金刚烷和酰胺结构的衍生物、其制备方法和用途 |
| CN104529855B (zh) * | 2015-01-13 | 2016-04-13 | 佛山市赛维斯医药科技有限公司 | 一种含羟基金刚烷和酰胺结构的衍生物、其制备方法和用途 |
| CN104478778B (zh) * | 2015-01-13 | 2016-03-16 | 佛山市赛维斯医药科技有限公司 | 金刚烷酰胺类衍生物、其制备方法和用途 |
| CN104447479B (zh) * | 2015-01-13 | 2016-03-23 | 佛山市赛维斯医药科技有限公司 | 含金刚烷和酰胺类衍生物、其制备方法和用途 |
| CN104496877B (zh) * | 2015-01-13 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一种腈基金刚烷酰胺衍生物、其制备方法和用途 |
| EP3273981B1 (en) | 2015-03-24 | 2020-04-29 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method and pharmaceutical composition for use in the treatment of diabetes |
| CN116509844B (zh) * | 2019-12-31 | 2024-06-04 | 石药集团中奇制药技术（石家庄）有限公司 | 一种二肽基肽酶4抑制剂的药物组合物及其制备方法和应用 |
| WO2021136491A1 (zh) * | 2019-12-31 | 2021-07-08 | 石药集团中奇制药技术（石家庄）有限公司 | 一种二肽基肽酶iv抑制剂的晶型及其制备方法和用途 |
| CN116375624A (zh) * | 2021-12-30 | 2023-07-04 | 石药集团中奇制药技术（石家庄）有限公司 | 吡咯烷类化合物的盐及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0910564B1 (en) * | 1995-11-28 | 2007-10-31 | Cephalon, Inc. | D-amino acid derived inhibitors of cysteine and serine proteases |
| JP2000264882A (ja) * | 1999-03-18 | 2000-09-26 | Nippon Shokubai Co Ltd | 有機アミド化合物およびその製造方法 |
| GB9928330D0 (en) * | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
| TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| CN100430386C (zh) * | 2002-11-07 | 2008-11-05 | 默克公司 | 苯丙氨酸衍生物作为二肽基肽酶抑制剂用于治疗或预防糖尿病 |
| JP4413863B2 (ja) * | 2002-11-07 | 2010-02-10 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療又は予防のためのジペチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体 |
| JP2004203526A (ja) | 2002-12-24 | 2004-07-22 | Sharp Corp | 記録装置 |
| AU2004207731B2 (en) | 2003-01-31 | 2009-08-13 | Sanwa Kagaku Kenkyusho Co., Ltd. | Compound inhibiting dipeptidyl peptidase iv |
| JP2007511467A (ja) | 2003-05-14 | 2007-05-10 | タケダ サン ディエゴ インコーポレイテッド | ジペプチジルペプチダーゼインヒビター |
| US20070093492A1 (en) * | 2004-03-09 | 2007-04-26 | Weir-Torn Jiaang | Pyrrolidine derivatives |
| KR100844593B1 (ko) * | 2004-03-09 | 2008-07-07 | 내셔날 헬스 리서치 인스티튜트 | 피롤리딘 화합물 |
| EP1760076A1 (en) * | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
-
2009
- 2009-02-25 JP JP2010549729A patent/JP5586484B2/ja active Active
- 2009-02-25 KR KR1020107021993A patent/KR101634656B1/ko active Active
- 2009-02-25 CA CA2717518A patent/CA2717518C/en active Active
- 2009-02-25 ES ES09718154.9T patent/ES2515194T3/es active Active
- 2009-02-25 US US12/392,590 patent/US8022096B2/en active Active
- 2009-02-25 CN CN2009801079412A patent/CN101970402B/zh active Active
- 2009-02-25 NZ NZ587911A patent/NZ587911A/en unknown
- 2009-02-25 BR BRPI0906094A patent/BRPI0906094B8/pt active IP Right Grant
- 2009-02-25 MY MYPI2010004155A patent/MY155630A/en unknown
- 2009-02-25 EP EP09718154.9A patent/EP2252582B1/en active Active
- 2009-02-25 WO PCT/US2009/035111 patent/WO2009111239A2/en not_active Ceased
- 2009-02-25 RU RU2010140627/04A patent/RU2494094C2/ru active
- 2009-02-25 AU AU2009222198A patent/AU2009222198B2/en active Active
- 2009-03-03 TW TW098106781A patent/TWI385163B/zh active
-
2010
- 2010-09-03 ZA ZA2010/06329A patent/ZA201006329B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101970402B (zh) | 2013-12-18 |
| RU2010140627A (ru) | 2012-04-10 |
| CA2717518A1 (en) | 2009-09-11 |
| AU2009222198B2 (en) | 2014-05-08 |
| WO2009111239A3 (en) | 2009-10-29 |
| ZA201006329B (en) | 2011-05-25 |
| TW200938530A (en) | 2009-09-16 |
| CA2717518C (en) | 2017-03-21 |
| HK1149261A1 (en) | 2011-09-30 |
| JP5586484B2 (ja) | 2014-09-10 |
| ES2515194T3 (es) | 2014-10-29 |
| US8022096B2 (en) | 2011-09-20 |
| WO2009111239A2 (en) | 2009-09-11 |
| JP2011513410A (ja) | 2011-04-28 |
| KR20100129754A (ko) | 2010-12-09 |
| EP2252582A2 (en) | 2010-11-24 |
| CN101970402A (zh) | 2011-02-09 |
| BRPI0906094B1 (pt) | 2019-11-12 |
| KR101634656B1 (ko) | 2016-06-29 |
| TWI385163B (zh) | 2013-02-11 |
| BRPI0906094B8 (pt) | 2021-05-25 |
| NZ587911A (en) | 2012-02-24 |
| RU2494094C2 (ru) | 2013-09-27 |
| MY155630A (en) | 2015-11-13 |
| AU2009222198A1 (en) | 2009-09-11 |
| EP2252582B1 (en) | 2014-07-23 |
| EP2252582A4 (en) | 2012-03-07 |
| US20090227569A1 (en) | 2009-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2024044I1 (no) | Insulin icodec | |
| BRPI0910854A2 (pt) | métodos de tratamento | |
| BRPI0910259A2 (pt) | métodos de tratamento de inflamação | |
| PL2190883T3 (pl) | Sposób obróbki biomasy | |
| LTPA2016041I1 (lt) | Gydymo būdai panaudojant vaistus - amoniako gaudykles | |
| BRPI1007477A2 (pt) | método, e, composição de tratamento de poço | |
| EP2320045A4 (en) | APPARATUS FOR TREATING EXHAUST GAS | |
| BRPI0920284A2 (pt) | composição e método | |
| DK2405869T3 (da) | Fedmebehandling | |
| EP2296593A4 (en) | MEDICAL HEAD COVER | |
| BRPI0910282A2 (pt) | Composto oxadiazo-antraceno para o tratamento de diabetes | |
| DK2330887T3 (da) | Behandlingsindretning | |
| FI20075978A0 (fi) | Järjestely ja menetelmä | |
| BRPI0919116A2 (pt) | método | |
| BRPI0919575A2 (pt) | método, e, composição | |
| IT1391555B1 (it) | Apparato trattamento extracorporeo sangue | |
| DK3338790T3 (da) | Oligopeptid-forbindelser og anvendelser deraf | |
| BRPI0810206A2 (pt) | Método de tratar câncer | |
| BRPI0917575A2 (pt) | métodos de tratamento de talassemia | |
| BRPI0823277A2 (pt) | Composição, e , método | |
| DK2361116T3 (da) | Bestrålingsindretning | |
| DK2313489T3 (da) | Fremstillingsmetode | |
| DE502008000740D1 (de) | Rollosystem | |
| DK2173831T3 (da) | Brøndbehandling | |
| LT3150178T (lt) | Stimuliavimo aparatas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/02/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |